Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7097610 | 0.83 | SCN8A (0.58) | SCN8ACYP1A2CYP2D6CHRM2ALDH1A1 | |
| SCHEMBL2983745 | 0.82 | DRD4 (0.54) | ALDH1A1DRD4 | |
| SCHEMBL3165235 | 0.81 | CYP2D6 (0.49) | CYP1A2CYP2D6ALDH1A1TP53POLB | |
| SCHEMBL10856250 | 0.80 | KMT2A (0.64) | SCN8ACYP1A2CYP2D6CHRM2ALDH1A1 | |
| SCHEMBL10857113 | 0.80 | ALDH1A1 (0.53) | SCN8ACYP1A2CYP2D6CHRM2ALDH1A1 | |
| SCHEMBL3154669 | 0.80 | CYP2D6 (0.58) | CYP1A2CYP2D6TDP1 | |
| SCHEMBL1044020 | 0.79 | CYP1A2 (0.75) | CYP1A2CYP2D6CHRM2ALDH1A1TP53 | |
| SCHEMBL864294 | 0.77 | MAPK1 (0.52) | ALDH1A1TP53POLBTDP1MAPK1 | |
| SCHEMBL19031318 | 0.77 | CYP1A2 (0.83) | SCN8ACYP1A2CYP2D6CHRM2ALDH1A1 | |
| SCHEMBL29875178 | 0.77 | CYP1A2 (0.83) | SCN8ACYP1A2CYP2D6CHRM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781591-B2 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC (US) | 2010-08-24 | — | — | US | disclosed |
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | CNKSR1, MAP3K1, MAP3K7 | SCN8A 1103/4885CYP1A2 2161/4885CYP2D6 2992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.